Table 4.
Checkpoint inhibitor clinical trials of NSCLC and MM.
| Immunotherapy | Patient Population | Response # (%) | Ref |
|---|---|---|---|
| BMS-936559 (anti-PD-L1) |
49 NSCLC | ORR: 5 (10.2) SD: 6 (12) PFS: (31) at 24 weeks |
190 |
| Chemotherapy + Ipilimumab (anti-CTLA-4) | 338 NSCLC (Stage IV or recurrent) | Median OS: 13.4 months Median PFS: 5.6 months AE (chemotherapy + ipilimumab): 173 (51) |
191 |
| BMS-936558 (anti-PD-1) |
76 NSCLC | ORR: 14 (18) SD: 5 (7) PFS: 20 (26) AE: 11 (14) |
192 |
| Pembrolizumab (anti-PD-1) |
690 NSCLC: 344 given 2 mg/kg 346 given 10 mg/kg |
2 mg/kg group: Median OS: 14.9 months Median PFS: 3.9 months 10 mg/kg group: Median OS: 17.3 months Median PFS: 4.0 months |
193 |
| Pembrolizumab (anti-PD-1) |
154 NSCLC: 29 squamous 125 non-squamous (18 Brain metastasis) |
ORR: 69 (45) Median time to respond: 2.2 months PFS: median 10.3 months (62.1% at 6 months) OS: 124 (80.2) at 6 months AE: 113 (73.4) |
194 |
| Nivolumab (anti-PD-1) |
135 NSCLC (non-squamous) (9 CNS metastasis) | ORR: 27 (20) PFS: median 3.5 months OS: 57 (42) 1 yr AE: 78 (58) |
195 |
| Nivolumab (anti-PD-1) |
52 NSCLC: 13 squamous 39 non-squamous (7 metastatic disease) |
ORR: 2 (15) squamous 10 (26) non-squamous AE: 10 (19) PFS: 21 (41) at 24 weeks OS: 38 (73) 1 yr |
196 |
| Nivolumab + ipilumab | 77 NSCLC | ORR: 33 (42.9) | 197 |
| Durvalumab (anti-PD-L1) |
473 NSCLC | Median PFS: 16.8 months PFS at 12 months: 264 (55.9) PFS at 18 months: 209 (44.2) ORR: 134 (28.4) |
198 |
| Nivolumab (anti-PD-1) |
292 NSCLC (non-squamous) | ORR: 56 (19) Median time to respond: 2.1 months OS: 149 (51) 1 yr (median 12.2 moths) PFS: median 2.3 months (19% at 12 months) |
199 |
| Pembrolizumab (anti-PD-1) |
495 NSCLC | ORR: 97 (19.4) Median time of response: 12.5 moths AE: 351 (70.9) SD: 21.8 (4.4) PFS: 3.7 months OS: median 12 months |
200 |
| Nivolumab and Nivolumab + Ipilimumab | 125 MPM: 63 given Nivo 62 given Nivo + Ipi |
ORR: Nivolumab: 11 (17.5) Nivolumab + Ipilimumab: 15 (24.2) |
201 |
| Nivolumab (anti-PD-1) |
34 MPM | DCR at 12 weeks: 17 (50) PR at 12 weeks: 5 (14.7) SD at 12 weeks: 12 (35.3 PD at 12 weeks: 17 (50) |
202 |
Key: Programmed Cell Death Protein-1 (PD-1), Programmed Death Receptor Ligand (PD-L1), Objective Response Rate (ORR), Stable Disease (SD), Progression Free Survival (PFS), Partial Response (PR), Complete Response (CR), Disease Control Rate (DCR), Stable Disease (SD), Progressive Disease (PD).